Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | DHFR | P00374 | 7/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619636 | 0.80 | LMNA (0.52) | DHFRHTR6 | |
| SCHEMBL31352975 | 0.76 | MTNR1B (0.56) | HTR6MTNR1B | |
| SCHEMBL3151230 | 0.76 | MTNR1B (0.56) | HTR6MTNR1B | |
| SCHEMBL8865965 | 0.75 | LMNA (0.56) | HTR6MTNR1B | |
| SCHEMBL5619791 | 0.75 | DHFR (0.44) | DHFR | |
| SCHEMBL14282636 | 0.74 | PGR (0.56) | HTR6MTNR1B | |
| SCHEMBL5619304 | 0.74 | DHFR (0.49) | DHFR | |
| SCHEMBL5358650 | 0.74 | DHFR (0.58) | DHFR | |
| SCHEMBL12325401 | 0.73 | PKM (0.70) | HTR6MTNR1B | |
| SCHEMBL6768236 | 0.72 | ADORA2A (0.63) | DHFRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040033934-A1 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | ARMY, UNITED STATES | 2004-02-19 | — | — | US | claimed |
| WO-2003069303-A2 | ANTIMALARIAL AND ANTIPROLIFERATIVE PHARMACOPHORE MODELS, NOVEL TRYPTANTHRIN COMPOUNDS HAVING INCREASED SOLUBILITY, AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2003-08-21 | — | — | WO | claimed |
| US-7259167-B2 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040033934-A1 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | ARMY, UNITED STATES | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033934-A1 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | TYR, MTTP, TPH2 | PDE4B 2489/4885DHFR 365/4885ADORA2A 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.